Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MEI Pharma (MEIP) has provided an announcement.
MEI Pharma, Inc. has announced a strategic evaluation of its options, which may include potential transactions or an orderly company wind-down to maximize asset value. Concurrently, the firm is halting clinical development of its drug voruciclib, while still pursuing some non-clinical activities. Details are outlined in a presentation material provided in their recent report, which contains forward-looking statements subject to risks and uncertainties. The company has clarified that the presentation’s content is not considered a material disclosure nor is it filed under securities law.
For detailed information about MEIP stock, go to TipRanks’ Stock Analysis page.